These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


333 related items for PubMed ID: 7628344

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Risk minimization evolution of agranulocytosis caused by the administration of pharmaceutical products containing Clozapine in Argentina].
    Bergman M, Bignone I, Bisio A, Bologna V, Sabatini A.
    Vertex; 2011; 22(96):94-7. PubMed ID: 21977603
    [Abstract] [Full Text] [Related]

  • 25. Optimizing clozapine treatment.
    Naber D.
    J Clin Psychiatry; 1999; 60 Suppl 12():35-8. PubMed ID: 10372609
    [Abstract] [Full Text] [Related]

  • 26. [A case of neutropenia and agranulocytosis induced by clozapine. The importance of a drug surveillance program for their early detection].
    Alfaro J, Berdichevsky E, Conte G, Tellez C.
    Rev Med Chil; 1994 Jun; 122(6):694-8. PubMed ID: 7732216
    [Abstract] [Full Text] [Related]

  • 27. Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients.
    Swartz JR, Ananth J, Smith MW, Burgoyne KS, Gadasally R, Arai Y.
    J Clin Psychiatry; 1999 Feb; 60(2):119-21. PubMed ID: 10084639
    [Abstract] [Full Text] [Related]

  • 28. [Problem of side effects of leponex on blood (multicenter inter- national study)].
    Panteleeva GP, Gamkrelidze ShA, Dikaia VI, Magalif AA, Okuneva TP, Perevozniuk AG, Shtemberg K, Filip V, German E, Zapletanek M.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991 Feb; 91(10):70-3. PubMed ID: 1665659
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview.
    Kane JM.
    Br J Psychiatry Suppl; 1992 May; (17):41-5. PubMed ID: 1418888
    [Abstract] [Full Text] [Related]

  • 31. Prevention of clozapine-induced granulocytopenia/agranulocytosis with granulocyte-colony stimulating factor (G-CSF) in an intellectually disabled patient with schizophrenia.
    Rajagopal G, Graham JG, Haut FF.
    J Intellect Disabil Res; 2007 Jan; 51(Pt 1):82-5. PubMed ID: 17181606
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Clozapine treatment in schizophrenia. A safety system is needed to prevent side effects].
    Lundström S, Persson P.
    Lakartidningen; 1991 Jul 24; 88(30-31):2510-1. PubMed ID: 1865717
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience.
    Alvir JM, Lieberman JA.
    J Clin Psychopharmacol; 1994 Apr 24; 14(2):87-9. PubMed ID: 8195462
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. White-blood-cell monitoring and clozapine.
    Finkel MJ, Arellano F.
    Lancet; 1995 Sep 23; 346(8978):849. PubMed ID: 7674782
    [No Abstract] [Full Text] [Related]

  • 38. [Agranulocytosis in the course of clozapine treatment].
    Załuska M, Gajewska J.
    Psychiatr Pol; 1995 Sep 23; 29(1):67-77. PubMed ID: 7878156
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 17.